Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib and SOX versus camrelizumab plus SOX versus SOX for conversion treatment of critically resectable gastric cancer
ChiCTR2000028845Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of camrelizumab, Rivoceranib, tegafur + gimeracil + oteracil and oxaliplatin in gastric cancer (GC) (3 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: R0 resection rate and Objective response rate. Started Jan 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranibtegafur + gimeracil + oteraciloxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2000028845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028845.